New formulation of clozapine approved

April 2004
Drug Topics;4/5/2004, Vol. 148 Issue 7, p8
Trade Publication
Reports on the U.S. Food & Drug Administration's approval of clozapine orally disintegrating tablet for the management of schizophrenic patients who are unresponsive to standard drug treatment.


Related Articles

  • Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents. Lyseng-Williamson, Katherine // Drugs & Therapy Perspectives;Jun2013, Vol. 29 Issue 6, p161 

    Clozapine, an atypical antipsychotic, is effective in the treatment of schizophrenia. However, its association with serious haematological toxicity has restricted its use to the management of patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agent, for...

  • Late-onset neutropenia due to clozapine. Baran Tatar, Zeynep; Yeşilyurt, Sema // Indian Journal of Psychiatry;Jul-Sep2015, Vol. 57 Issue 3, p325 

    The article presents the case of a middle-aged woman whose neutropenia is attributed to antipsychotic drug clozapine. Topics include the lower risk of extrapyramidal side effects carried by clozapine, the importance of regular blood monitoring in patients treated with clozapine, and the risk of...

  • Myoclonus as an indicator of infection in patients with schizophrenia treated with clozapine.  // Journal of Psychiatry & Neuroscience;Jan2011, Vol. 36 Issue 1, pE1 

    The article discusses the case study of a 60 year old Chinese woman, with a history of schizophrenia, and paroxysmal unstable gait due to leg folding, who was successfully treated with Clozapine. There was an occurrence of myoclonus which indicated prevalence asymptomatic pneumonia. It...

  • Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia. Eryılmaz, Gül; Sayar, Gökben Hızlı; Ozten, Eylem; Gül, Işıl Gögcegöz; Karamustafalıoğlu, Oğuz // Annals of General Psychiatry;2013, Vol. 12 Issue 1, p40 

    Objective Patients with schizophrenia often experience comorbid obsessive-compulsive symptoms. Within these patients, a significant subgroup developed secondary obsessive-compulsive symptoms during treatment with clozapine. Method In this paper, we report on four cases in which adjunctive...

  • Successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia. Kumar, Vijaya; Sharma, Lavanya; Madival, Srikanth; Venkatasubramanian, Ganesan // Journal of Psychiatry & Neuroscience;Jan2016, Vol. 41 Issue 1, pE1 

    The article describes the case of a 57 year old woman with treatment-resistant schizophrenia who was started on clozapine to augment her ongoing treatment with olanzapine. The adverse effects decreased after the caregiver changed her medication regimen where she was given 15 milligram (mg) of...

  • Pseudoephedrine for the Treatment of Clozapine-Induced Incontinence. Hanes, Alicia; Demler, Tammie Lee; Lee, Claudia; Campos, Alexander // Innovations in Clinical Neuroscience;Apr2013, Vol. 10 Issue 4, p33 

    Clozapine, the first atypicalantipsychotic, is well known for superior efficacy in the treatment of refractory schizophrenia. Though the side effect most often associated with clozapine is the potential for causing blood dyscrasias, other lesser known side effects, including clozapine-induced...

  • Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns. Janno, Sven; Holi, Matti M.; Tuisku, Katinka; Wahlbeck, Kristian // BMC Neurology;2008, Vol. 8, Special section p1 

    Background: Neuroleptic-induced movement disorders (NIMDs) have overlapping co-morbidity. Earlier studies have described typical clinical movement patterns for individual NIMDs. This study aimed to identify specific movement patterns for each individual NIMD using actometry. Methods: A...

  • NEUROPSYCHIATRY. Blomgren, Donna // Journal of Pharmacy Practice & Research;Sep2012, Vol. 42 Issue 3, p241 

    The article offers abstracts on neuropsychiatry topics which include a case study of delirium in a Sheehan’s Syndrome patient, risk factors for suicide, and the addition of sertindole to a clozapine regimen for the prevention of cognitive impairment in schizophrenia.

  • Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Davies, Linda M.; Drummond, Michael F.; Davies, L M; Drummond, M F // British Journal of Psychiatry;Jan93, Vol. 162, p38 

    An analysis was conducted on the basis of available data to assess the economic consequences of clozapine therapy for people with moderate to severe schizophrenia in long-stay institutions or staffed group homes, with a view to providing an estimate of the likely costs and benefits of the drug....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics